Imagia’s mission is to detect and quantify cancer changes early. When it matters. Despite systematic imaging and new genetic testing, tumor changes are often detected too late to improve cancer patient outcomes. Our Artificial Clinical Intelligence Platform enables us to provide critical information and timely imaging insights for primary tumors and metastasis for each cancer patient thus personalizing their cancer care continuum. Deep Radiomics™ — uniting radiomics and deep learning — utilizes existing routine clinical imaging data to discover robust imaging biomarkers that predict cancer patient outcomes.

Imagia’s mission is to detect and quantify cancer changes early. When it matters. Despite systematic imaging and new genetic testing, tumor changes are often detected too late to improve cancer patient outcomes. Our Artificial Clinical Intelligence Platform enables us to provide critical information and timely imaging insights for primary tumors and metastasis for each cancer patient thus personalizing their cancer care continuum. Deep Radiomics™ — uniting radiomics and deep learning — utilizes existing routine clinical imaging data to discover robust imaging biomarkers that predict cancer patient outcomes.

EyeArt is the first and only FDA-cleared AI technology for autonomous detection of both more than mild and vision-threatening diabetic retinopathy. The EyeArt® AI Eye Screening System is the most extensively validated autonomous AI technology, tested on over half a million patient visits globally with over two million images collected in real-world clinical environments.It is proven to be safe, fast, and consistent.